Seelos Therapeutics Management
Management criteria checks 3/4
Seelos Therapeutics' CEO is Raj Mehra, appointed in Jan 2019, has a tenure of 5.33 years. total yearly compensation is $1.73M, comprised of 34% salary and 66% bonuses, including company stock and options. directly owns 1.35% of the company’s shares, worth $58.54K. The average tenure of the management team and the board of directors is 4 years and 5.3 years respectively.
Key information
Raj Mehra
Chief executive officer
US$1.7m
Total compensation
CEO salary percentage | 34.0% |
CEO tenure | 5.3yrs |
CEO ownership | 1.4% |
Management average tenure | 4yrs |
Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Seelos: Data This Year Is Critical
Oct 04Seelos wins Parkinson’s research grant for gene therapy program
Aug 24Seelos: FDA Action Makes It Highly Attractive
Dec 22Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains
Oct 01We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely
Aug 18Seelos: Superior Data, But Early Stage
Jun 09Seelos announces issuance of a patent for trehalose (SLS-005) in Australia
Jan 29Seelos' expects to commence SLS-005 study in rare neurological disease in H1 2021, shares up 6%
Jan 06Seelos Therapeutics' trehalose nabs Israel patent
Dec 21Seelos Therapeutics (SEEL) files for $200M mixed shelf, shares down 8%
Dec 16Seelos nabs US Orphan Drug status for SLS-005 in amyotrophic lateral sclerosis
Nov 19CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$587k | -US$38m |
Sep 30 2023 | n/a | n/a | -US$51m |
Jun 30 2023 | n/a | n/a | -US$81m |
Mar 31 2023 | n/a | n/a | -US$73m |
Dec 31 2022 | US$2m | US$562k | -US$74m |
Sep 30 2022 | n/a | n/a | -US$82m |
Jun 30 2022 | n/a | n/a | -US$73m |
Mar 31 2022 | n/a | n/a | -US$61m |
Dec 31 2021 | US$16m | US$523k | -US$66m |
Sep 30 2021 | n/a | n/a | -US$45m |
Jun 30 2021 | n/a | n/a | -US$39m |
Mar 31 2021 | n/a | n/a | -US$33m |
Dec 31 2020 | US$4m | US$475k | -US$19m |
Sep 30 2020 | n/a | n/a | -US$23m |
Jun 30 2020 | n/a | n/a | -US$22m |
Mar 31 2020 | n/a | n/a | -US$21m |
Dec 31 2019 | US$709k | US$438k | -US$51m |
Compensation vs Market: Raj's total compensation ($USD1.73M) is above average for companies of similar size in the US market ($USD667.96K).
Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.
CEO
Raj Mehra (63 yo)
5.3yrs
Tenure
US$1,726,476
Compensation
Dr. Raj Mehra, Ph D., J.D., was an Independent Director at Larkspur Health Acquisition Corp. since July 2021 and serves as its Director. He was Chairman of Seelos Therapeutics, Inc & serves as Chief Execut...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, Founder | 5.3yrs | US$1.73m | 1.35% $ 58.5k | |
Chief Financial Officer | 2.7yrs | US$846.67k | 0.63% $ 27.5k | |
Chief Communications Officer | 5.3yrs | no data | no data | |
Head of Manufacturing & Technical Operations | no data | no data | no data | |
Chief Medical Officer | no data | no data | no data | |
Senior VP & Head of Clinical Operations | 1.5yrs | no data | no data |
4.0yrs
Average Tenure
Experienced Management: SEEL's management team is considered experienced (4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | 2.7yrs | US$89.72k | 0.0085% $ 369.0 | |
Independent Chairman | 11.2yrs | US$87.72k | 0.0013% $ 54.5 | |
Independent Director | 5.3yrs | US$74.22k | 0.0039% $ 168.7 | |
Independent Director | 5.3yrs | US$105.22k | 0% $ 0 |
5.3yrs
Average Tenure
58.5yo
Average Age
Experienced Board: SEEL's board of directors are considered experienced (5.3 years average tenure).